Virology & Infectious Diseases RFP Opportunities
Gilead Sciences offers funding for research advancing HIV prevention, treatment, integrated hepatitis care, and fungal disease management to improve clinical outcomes and health equity.
Funder: Gilead Sciences
Due Dates: April 3, 2026 (Full application — INCLUSION Global 2026) | May 4, 2026 (LOI — RESONATE RFP) | May 29, 2026 (Full application — RESONATE RFP) | June 30, 2026 (LOI — AmBisome RFP) | July 12, 2026 (LOI — GATHER AND LISTEN 2026)
Funding Amounts: Up to $5,000,000 (INCLUSION Global 2026) and $4,000,000 (RESONATE RFP) total program budgets; individual proposals typically up to $500,000–$1,000,000; project durations up to 18–24 months.
Summary: Supports investigator-initiated and collaborative research to advance HIV prevention, treatment, and integrated viral hepatitis/fungal disease care.
Key Information: Strict eligibility by geography/topic; LOI required before full application; overhead capped at 30%.
Description
Gilead Sciences offers multiple Request for Proposal (RFP) opportunities to fund high-impact research in virology and infectious diseases, including HIV prevention and management, integrated HIV and hepatitis care, and fungal disease epidemiology and treatment. These highly competitive RFPs support investigator-initiated and collaborative studies that address critical scientific questions, implementation challenges, and health equity barriers in HIV, hepatitis B/C/D, and invasive fungal diseases. Funding is available for research that informs clinical decision-making, enhances care models, and improves patient outcomes, with a focus on studies that can be completed within 18–24 months.
